Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation

DNA methyltransferase inhibitor (DNMTi) treatments have been used for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and have shown promising beneficial effects in some other types of cancers. Here, we demonstrate that the transcriptional repressor ZBTB38 is a critic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncogenesis
Main Authors: Marchal, Claire, de Dieuleveult, Maud, Saint-Ruf, Claude, Guinot, Nadège, Ferry, Laure, Olalla Saad, Sara T., Lazarini, Mariana, Defossez, Pierre-Antoine, Miotto, Benoit
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182000/
https://ncbi.nlm.nih.gov/pubmed/30310057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0092-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares